

**Supplemental Figure 7: VAC treatment did not improve therapeutic efficacy of DOTA-EB-TATE in either low- or high-SSTR2 expressing tumors.**

(A) No effect of VAC on the tumor progression in the 177Lu-DOTA-EB-TATE treated FTC133 (low-SSTR2-expressing) subcutaneous xenograft mice model. C–control mice that received 177Lu-DOTA-EB-TATE (n=8); VAC–valproic acid treated mice that received 177Lu-DOTA-EB-TATE (n=9). Data are presented as mean±SEM.

(B) No effect of VAC on the tumor progression in the 177Lu-DOTA-EB-TATE treated AR42J (high-SSTR2-expressing) subcutaneous xenograft mice model. C–control mice that received 177Lu-DOTA-EB-TATE (n=8); VAC–valproic acid treated mice that received 177Lu-DOTA-EB-TATE (n=7). Data are presented as mean±SEM.